Home | About the eMC | Help | Mobile
eMC - trusted, up to date and comprehensive information about medicines
Link to eMC medicine guides website
eMC homepage
Advanced search
Get Medicines Compendium UK app here

Winthrop Pharmaceuticals UK Ltd
One Onslow Street, Guildford, Surrey, GU1 4YS, UK
Telephone: +44 (0)1483 505 515
Fax: +44 (0)1483 554 831
E-mail: UK-medicalinformation@sanofi-aventis.com
Medical Information Direct Line: +44 (0)1483 554 101
Medical Information Fax: +44 (0)1483 554 831

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?
Summary of Product Characteristics last updated on the eMC: 18/09/2007
SPC Neulactil Tablets

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 18/09/2007 and displayed until Current
Reasons for adding or updating:
  • Change to section 7 - Marketing Authorisation Holder
Date of revision of text on the SPC:   08/2007
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company

Change of product licence holder to trading style of sanofi aventis
Updated on 21/09/2006 and displayed until 18/09/2007
Reasons for adding or updating:
  • Change to section 6.1 - List of Excipients
Date of revision of text on the SPC:   08/2006
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company
Section 6.1 (List of excipients): Change to the specification of Lactose anhydrous ffrom USP to Ph. Eur.
Updated on 04/08/2006 and displayed until 21/09/2006
Reasons for adding or updating:
  • Change to section 4.8 - Undesirable Effects
Date of revision of text on the SPC:   03/2003
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company
 
Section 4.8 (undesirable effects): Liver function: Liver injury has been reported very rarely in in patients treated with pericyazine.
 
Section 4.8 (undesirable effects): Liver function: Neuroleptic jaundice has the biochemical and other characteristics of obstructive (cholestatic) jaundice....
 
Section 4.8 (undesirable effects):  Priapism has very rarely been reported in patients treated with pericyazine.
Updated on 24/09/2004 and displayed until 04/08/2006
Reasons for adding or updating:
  • Improved Electronic Presentation
Updated on 24/09/2004 and displayed until 24/09/2004
Reasons for adding or updating:
  • Improved Electronic Presentation
Updated on 24/09/2004 and displayed until 24/09/2004
Reasons for adding or updating:
  • New SPC for eMC ie an SPC for an existing product, but one that is new for the eMC

Active Ingredients/Generics

 
  pericyazine